Announcements Trials
Browse Landscape

Phase

Phase 2 26Phase 1 4Phase 1/2 3Phase EARLY_PHASE1 2Phase 4 2Phase 3 2Phase NA 1Phase 2/3 1

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Gastrointestinal 3Head & Neck 2Gynecologic 2Dermatologic 2Breast 2Sarcoma 1Other solid neoplasm 1CNS 1

Conditions

Prostatic Neoplasms 1Prostate Cancer Recurrent 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 69Docetaxel 50Nivolumab 44Prednisone 34enzalutamide 30Gemcitabine 26Cyclophosphamide 22Cisplatin 22Paclitaxel 21Radiotherapy 19Carboplatin 19Bevacizumab 19Abiraterone Acetate 18Ipilimumab 17atezolizumab 14Magnetic Resonance Spectroscopy 14fludarabine 13aldesleukin 13Sunitinib 13Interleukin-2 12avelumab 11Radiosurgery 11Pluvicto 11Filgrastim 11Everolimus 11gallium 68 PSMA-11 10fludarabine phosphate 10enfortumab vedotin 10durvalumab 10cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Metformin × Genitourinary × Clear all
NCT05036226 2026-05-13

COAST

Medical University of South Carolina

Phase 1/2 Recruiting
76 enrolled
GenitourinaryOther solid neoplasm

Prostate Cancer Recurrent

NCT04536805 2025-12-08

REPAIR

Institut Cancerologie de l'Ouest

Phase 1/2 Recruiting
44 enrolled
Genitourinary

Prostatic Neoplasms

NCT02495103 2021-01-26

Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
7 enrolled 10 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡